Latest1 information on COVID-19
©2022 Stanford Medicine
Recruiting
I'm InterestedTrial ID: NCT04250155
A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Assistant Professor of Medicine (Oncology)
Key General Inclusion Criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy >/= 12 weeks
- Adequate hematologic and end-organ function
- For participants receiving therapeutic anticoagulation: stable anticoagulant regimen
- Negative serum pregnancy test for women of childbearing potential
- Histologically confirmed locally advanced, recurrent, or metastatic incurable solid
tumor malignancy
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Availability of representative tumor specimens
Key General Exclusion Criteria
- Pregnant or breastfeeding, or intending to become pregnant during the study
- Significant cardiovascular disease
- Current treatment with medications that prolong the QT interval
- Known clinically significant liver disease
- Poorly controlled Type 2 diabetes mellitus
- Symptomatic, untreated, or actively progressing CNS metastases
- History of leptomeningeal disease
- History of malignancy other than disease under study within 3 years prior to screening
- Active or history of autoimmune disease or immune deficiency
- Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus
infection
- Positive for HIV infection
- Prior allogeneic stem cell or solid organ transplantation
drug: XmAb24306
drug: Atezolizumab
drug: XmAb24306
Recruiting
I'm Interested
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Team Phase 1
Phase1Team@stanfordhealthcare.org